A	B	C
1	Main
2		Brand Name
3		Generic Name	enzastaurin
4		Indication	NHL
5		Mechanism	serine-threonine kinase inhibitor; PKC-beta, PI3K/AKT
6		Clinical Trials
7			Phase III "PRELUDE" trial in maintenance/prevention of relapse diffuse large-b-cell lymphoma (DLBCL)
8			n=459, primary endpoint is DFS
9
10			GBM phase 3 - STEERING - randomized open-label enza vs lomustine. N=397, OS and PFS primary endpoints
11			DMC recommends STEERING be halted. Development for GBM stopped.